S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com - Morgan Stanley (NYSE:MS) has lowered its price target on Colgate-Palmolive Company (NYSE:CL) to $96.00 from $104.00 while maintaining an Overweight rating on the stock. The company currently trades at $83.19, near its 52-week low of $82.70, with analyst targets ranging from $83 to $106. According to InvestingPro data, the stock shows signs of being slightly undervalued based on its proprietary Fair Value model.
The firm indicated it holds a mixed view on Colgate-Palmolive, noting it finds itself "in the odd position of both sympathizing with some of the bull and bear market views" on the company’s stock.
Morgan Stanley considers Colgate-Palmolive as "relatively well positioned" compared to other household and personal care peers in its coverage universe.
The research firm clarified that despite the positive relative positioning, it does not view Colgate-Palmolive as attractive as its top Overweight-rated companies outside the household and personal care sector.
Morgan Stanley specifically mentioned it prefers Overweight-rated stocks including Coca-Cola (NYSE:KO), Keurig Dr Pepper (NASDAQ:KDP), Philip Morris (NYSE:PM), and Monster Beverage (NASDAQ:MNST), which it favors both for short-term and longer-term investment horizons.
In other recent news, Colgate-Palmolive Company reported its second-quarter earnings for 2025, surpassing analyst expectations with an earnings per share (EPS) of $0.92, slightly above the forecasted $0.90. The company also exceeded revenue forecasts, achieving $5.11 billion against the anticipated $5.03 billion. Despite these positive financial results, investor sentiment remains mixed, as reflected in various analyst ratings and price target adjustments. Morgan Stanley lowered its price target for Colgate-Palmolive to $96 while maintaining an Overweight rating. Evercore ISI reiterated an Outperform rating with a price target of $100, noting the company’s effective strategy and 2% organic sales growth despite market volatility. UBS also maintained its Buy rating with a $106 price target, highlighting that the company’s earnings and sales growth exceeded both its own and market expectations. These developments indicate a complex investor outlook on Colgate-Palmolive, with analysts providing varied perspectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.